Four very recent articles and presentations have addressed issues relevant to the use of the PSA test in testing/screening for risk of prostate cancer. An extremely detailed article by Roth et al. in this week’s JAMA Oncology has used sophisticated modeling techniques to examine the economics of testing/screening for and then treating (or just monitoring) […]![]()
